The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain

Molecular Cell

Volumn 13, Issue 2, 2004, Pages 169-178

  Griffith, James ^a   Black, James ^a   Faerman, Carlos ^a   Swenson, Lora ^a   Wynn, Michael ^a   Lu, Fan ^a   Lippke, Judith ^a   Saxena, Kumkum ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; PROTEIN DOMAIN; STRUCTURE ANALYSIS;

EID: 0842310394     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00505-7     Document Type: Article

References (58)

1. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R., Reilly J.T. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. 113:2001;983-988.
2. Agnes F., Shamoon B., Dina C., Rosnet O., Birnbaum D., Galibert F. Genomic structure of the downstream part of the human FLT3 gene. exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III Gene. 145:1994;283-288.
3. Bohmer F.D., Karagyozov L., Uecker A., Serve H., Botzki A., Mahboobi S., Dove S. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. 278:2003;5148-5155.
4. Bossemeyer D., Engh R.A., Kinzel V., Ponstingl H., Huber R. Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J. 12:1993;849-859.
5. Brasel K., Escobar S., Anderberg R., de Vries P., Gruss H.J., Lyman S.D. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia. 9:1995;1212-1218.
6. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography & NMR system. a new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54:1998;905-921.
7. CCP4 The CCP4 (Collaborative Computational Project 4) suite. programs for protein crystallography Acta Crystallogr. D. 50:1994;760-763.
8. Chan P.M., Ilangumaran S., La Rose J., Chakrabartty A., Rottapel R. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol. Cell Biol. 23:2003;3067-3078.
9. deLapeyriere O., Naquet P., Planche J., Marchetto S., Rottapel R., Gambarelli D., Rosnet O., Birnbaum D. Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues. Differentiation. 58:1995;351-359.
10. Drexler H.G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia. 10:1996;588-599.
11. Fabbro D., Ruetz S., Bodis S., Pruschy M., Csermak K., Man A., Campochiaro P., Wood J., O'Reilly T., Meyer T. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 15:2000;17-28.
12. Giles F.J., Stopeck A.T., Silverman L.R., Lancet J.E., Cooper M.A., Hannah A.L., Cherrington J.M., O'Farrell A.M., Yuen H.A., Louie S.G.et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 102:2003;795-801.
13. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood. 100:2002;1532-1542.
14. Hayakawa F., Towatari M., Kiyoi H., Tanimoto M., Kitamura T., Saito H., Naoe T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 19:2000;624-631.
15. Heldin C.H. Dimerization of cell surface receptors in signal transduction. Cell. 80:1995;213-223.
16. Horiike S., Yokota S., Nakao M., Iwai T., Sasai Y., Kaneko H., Taniwaki M., Kashima K., Fujii H., Abe T., Misawa S. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 11:1997;1442-1446.
17. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16:1997;5572-5581.
18. Hubbard S.R., Wei L., Ellis L., Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 372:1994;746-754.
19. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell. 109:2002;275-282.
20. Huse M., Chen Y.G., Massague J., Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell. 96:1999;425-436.
21. Irusta P.M., Luo Y., Bakht O., Lai C., Smith S.O., DiMaio D. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor β receptor. J. Biol. Chem. 277:2002;38627-38634.
22. Kelly L.M., Yu J.C., Boulton C.L., Apatira M., Li J., Sullivan C.M., Williams I., Amaral S.M., Curley D.P., Duclos N.et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 1:2002;421-432.
23. Knighton D.R., Zheng J.H., Ten Eyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:1991;407-414.
24. Kottaridis P.D., Gale R.E., Linch D.C. Flt3 mutations and leukaemia. Br. J. Haematol. 122:2003;523-538.
25. Lyman S.D., Williams D.E. Biology and potential clinical applications of flt3 ligand. Curr. Opin. Hematol. 2:1995;177-181.
26. Lyman S.D., James L., Johnson L., Brasel K., de Vries P., Escobar S.S., Downey H., Splett R.R., Beckmann M.P., McKenna H.J. Cloning of the human homologue of the murine flt3 ligand. a growth factor for early hematopoietic progenitor cells Blood. 83:1994;2795-2801.
27. Maroc N., Rottapel R., Rosnet O., Marchetto S., Lavezzi C., Mannoni P., Birnbaum D., Dubreuil P. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene. 8:1993;909-918.
28. Matthews W., Jordan C.T., Wiegand G.W., Pardoll D., Lemischka I.R. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 65:1991;1143-1152.
29. McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.C., Villafranca J.E., Appelt K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2. a key enzyme in angiogenesis Struct. Fold. Des. 7:1999;319-330.
30. Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C., Gruning W., Kratz-Albers K., Serve S., Steur C.et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 96:2000;3907-3914.
31. Mizuki M., Schwable J., Steur C., Choudhary C., Agrawal S., Sargin B., Steffen B., Matsumura I., Kanakura Y., Bohmer F.D.et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 101:2003;3164-3173.
32. Mohammadi M., Froum S., Hamby J.M., Schroeder M.C., Panek R.L., Lu G.H., Eliseenkova A.V., Green D., Schlessinger J., Hubbard S.R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17:1998;5896-5904.
33. Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y., Sang B.C., Nowakowski J., Kassel D.B., Cronin C.N., McRee D.E. Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation. J. Biol. Chem. 278:2003;31461-31464.
34. Munshi S., Kornienko M., Hall D.L., Reid J.C., Waxman L., Stirdivant S.M., Darke P.L., Kuo L.C. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity. J. Biol. Chem. 277:2002;38797-38802.
35. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 10:1996;1911-1918.
36. Navaza J. AmoRe. an automated package for molecular replacement Acta Crystallogr. A. 50:1994;157-163.
37. Niu X.L., Peters K.G., Kontos C.D. Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism. J. Biol. Chem. 277:2002;31768-31773.
38. O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., Wong L.M., Hong W., Lee L.B., Town A.et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 101:2003;3597-3605.
39. Rosnet O., Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit. Rev. Oncog. 4:1993;595-613.
40. Rosnet O., Marchetto S., deLapeyriere O., Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene. 6:1991;1641-1650. a.
41. Rosnet O., Mattei M.G., Marchetto S., Birnbaum D. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics. 9:1991;380-385. b.
42. Rosnet O., Schiff C., Pebusque M.J., Marchetto S., Tonnelle C., Toiron Y., Birg F., Birnbaum D. Human FLT3/FLK2 gene. cDNA cloning and expression in hematopoietic cells Blood. 82:1993;1110-1119.
43. Rosnet O., Buhring H.J., deLapeyriere O., Beslu N., Lavagna C., Marchetto S., Rappold I., Drexler H.G., Birg F., Rottapel R.et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol. 95:1996;218-223.
44. Savvides S.N., Boone T., Andrew Karplus P. Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots. Nat. Struct. Biol. 7:2000;486-491.
45. Sawyers C.L. Finding the next Gleevec. FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia Cancer Cell. 1:2002;413-415.
46. Scheijen B., Griffin J.D. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 21:2002;3314-3333.
47. Schlessinger J. Signal transduction. Autoinhibition control. Science. 300:2003;750-752.
48. Spiekermann K., Dirschinger R.J., Schwab R., Bagrintseva K., Faber F., Buske C., Schnittger S., Kelly L.M., Gilliland D.G., Hiddemann W. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 101:2003;1494-1504.
49. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:2002;46265-46272.
50. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer. 3:2003;650-665.
51. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., Wermke M., Bornhauser M., Ritter M., Neubauer A.et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia. association with FAB subtypes and identification of subgroups with poor prognosis Blood. 99:2002;4326-4335.
52. Till J.H., Becerra M., Watty A., Lu Y., Ma Y., Neubert T.A., Burden S.J., Hubbard S.R. Crystal structure of the MuSK tyrosine kinase. insights into receptor autoregulation Structure. 10:2002;1187-1196.
53. Turner A.M., Lin N.L., Issarachai S., Lyman S.D., Broudy V.C. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood. 88:1996;3383-3390.
54. Weisberg E., Boulton C., Kelly L.M., Manley P., Fabbro D., Meyer T., Gilliland D.G., Griffin J.D. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:2002;433-443.
55. Wybenga-Groot L.E., Baskin B., Ong S.H., Tong J., Pawson T., Sicheri F. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell. 106:2001;745-757.
56. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., Asou N., Kuriyama K., Yagasaki F., Shimazaki C.et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 97:2001;2434-2439.
57. Yokota S., Kiyoi H., Nakao M., Iwai T., Misawa S., Okuda T., Sonoda Y., Abe T., Kahsima K., Matsuo Y.et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 11:1997;1605-1609.
58. Zhang S., Fukuda S., Lee Y., Hangoc G., Cooper S., Spolski R., Leonard W.J., Broxmeyer H.E. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J. Exp. Med. 192:2000;719-728.